Skip to main content
Premium Trial:

Request an Annual Quote

Nuclidium, Guerbet Ink Deal to Develop Targeted Copper-Based Radiopharmaceuticals

NEW YORK – Nuclidium and Guerbet said on Wednesday that they have inked a deal to jointly develop Nuclidium's copper-based radiopharmaceuticals. 

Under the collaboration, Villepinte, France-based Guerbet will provide its diagnostic imaging, manufacturing, and clinical trials knowledge and networks to help advance Basel, Switzerland-based Nuclidium's theranostic candidates, which include copper-based diagnostic radiopharmaceuticals using the isotope 61Cu and therapeutic radiopharmaceuticals using the isotope 67Cu. 

Nuclidium's pipeline includes targeted preclinical and clinical-stage radiopharmaceutical candidates such as NuriPro, a theranostic for patients with prostate-specific antigen (PSMA)-expressing prostate cancer; Kalios, a theranostic for fibroblast activation protein-overexpressing epithelial cancers; and TraceNET, a theranostic for somatostatin receptor (SSTR)-expressing neuroendocrine cancers. 

As part of the deal, Guerbet has also invested a nonexclusive, undisclosed amount in Nuclidium, and Guerbet Senior VP of R&D Francois Nicolas will join Nuclidium's board of directors as an observer. 

"Targeted radiopharmaceuticals represent a significant advancement in cancer treatment, yet face supply limitations and production challenges," Nicolas said in a statement. "Nuclidium's copper-based strategy presents a promising approach to address these issues, enhancing patient access and improving disease staging and treatment."